[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-295989-105":59,"doc-detail-295989-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","kdigo-2025-clinical-practice-guideline-autosomal-dominant-polycystic-kidney-disease-adpkd","KDIGO 2025 Clinical Practice Guideline - Autosomal Dominant Polycystic Kidney Disease (ADPKD)","","KDIGO 2025 provides a comprehensive clinical practice guideline supplement for evaluating, managing, and treating autosomal dominant polycystic kidney disease (ADPKD). The supplement spans nomenclature, diagnosis, prognosis, and epidemiology, then kidney manifestations, CKD management and progression, kidney failure, and kidney replacement therapy. It includes therapies to delay disease progression, extrarenal involvement such as polycystic liver disease and intracranial aneurysms, and addresses lifestyle, psychosocial factors, pregnancy, reproductive issues, and pediatric considerations.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/kdigo-2025-clinical-practice-guideline-autosomal-dominant-polycystic-kidney-disease-adpkd/295989/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/kdigo-2025-clinical-practice-guideline-autosomal-dominant-polycystic-kidney-disease-adpkd/295989.png","ImageObject",300,407,{"name":92,"@type":93},"Sage","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-21","2026-09-18",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",22,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What conditions and topics does the KDIGO 2025 ADPKD guideline supplement cover?","Question",{"text":113,"@type":114},"It covers evaluation and management of ADPKD across diagnosis, prognosis, and prevalence, kidney manifestations, CKD progression, kidney failure and kidney replacement therapy, and therapies intended to delay progression. It also addresses extrarenal manifestations including polycystic liver disease and intracranial aneurysms, plus lifestyle, psychosocial aspects, pregnancy and reproductive issues, and pediatric issues.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"Which clinical chapters focus on delaying progression and related therapies?",{"text":118,"@type":114},"The supplement includes Chapter 4 on therapies to delay progression of kidney disease and also includes content on approaches to delay disease progression and reduce relevant biological activity, along with related contraindication and consideration tables.",{"name":120,"@type":111,"acceptedAnswer":121},"Does the supplement include appendices for patient-centered outcomes and patient journey checklists?",{"text":122,"@type":114},"Yes. Appendix 1 lists patient-reported outcome measures (PROMs) in ADPKD care, Appendix 2 provides a recommended checklist of issues to discuss at the beginning of the patient journey, and Appendix 3 lists patient organizations and other useful resources.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},295989,1789726619,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":130,"read_time":145},687197207057,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","SUPPLEMENT TO  \nKDIGO 2025 Clinical Practice Guideline for the Evaluation, Management, and Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)  \nVOLUME 107 | ISSUE 2S | FEBRUARY 2025 [www.kidney-international.org](www.kidney-international.org)  \nKDIGO 2025 CLINICAL PRACTICE GUIDELINE FOR THE EVALUATION, MANAGEMENT, AND TREATMENT OF AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD)  \nKidney International (2025) 107 (Suppl 2S), S1–S239 S1  \nVOL 107 | ISSUE 2S | FEBRUARY 2025  \nKDIGO 2025 Clinical Practice Guideline for the Evaluation, Management, and Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)  \nS3 Table list, figure list, and supplementary material  \nS7 KDIGO Executive Committee  \nS8 Reference keys  \nS9 Current chronic kidney disease (CKD) nomenclature used by KDIGO  \nS10 Conversion factors of conventional units to SI units  \nS10 Equivalent albuminuria categories in CKD  \nS11 Abbreviations and acronyms  \nS13 Notice  \nS14 Foreword  \nS15 Dedication  \nS17 Work Group membership  \nS19 Abstract  \nS20 Introduction from the Guideline Co-Chairs  \nS22 Summary of recommendation statements and practice points  \nS56 Chapter 1: Nomenclature, diagnosis, prognosis, and prevalence  \nS85 Chapter 2: Kidney manifestations  \nS99 Chapter 3: Chronic kidney disease (CKD) management and progression,  \nkidney failure, and kidney replacement therapy (KRT) S112 Chapter 4: Therapies to delay the progression of kidney disease  \nS134 Chapter 5: Polycystic liver disease  \nS146 Chapter 6: Intracranial aneurysms and other extrarenal manifestations  \nS158 Chapter 7: Lifestyle and psychosocial aspects  \nS168 Chapter 8: Pregnancy and reproductive issues  \nS176 Chapter 9: Pediatric issues  \nS187 Chapter 10: Approaches to the management of people with ADPKDS191 Methods for guideline development  \nS205 Biographic and disclosure information S216 Acknowledgments  \nS217 References  \nS236 Appendix 1: Patient-reported outcome measures (PROMs) in ADPKD care  \nS238 Appendix 2: Recommended checklist of issues to discuss at the beginning of the patient journey  \nS239 Appendix 3: Patient organizations dealing with ADPKD or kidney disease in general, and other useful resources for patients and healthcare providers  \nThis article is published as part of a supplement sponsored by Kidney Disease: Improving Global Outcomes (KDIGO) .  \nS2 Kidney International (2025) 107 (Suppl 2S), S1–S239  \nTABLES  \nS57 Table 1. Genes associated with the ADPKD spectrum, designations, and phenotype  \nS58 Table 2. Genes associated with the ADPLD spectrum, designations, and phenotype  \nS64 Table 3. Factors to consider when testing (by imaging and/or genetics) people at risk for ADPKD  \nS25 Table 4. Situations in which genetic testing can clarify the diagnosis and aid in determining a prognosis  \nS26 Table 5. Other disorders that present with kidney cysts  \nS72 Table 6. Genetic testing methods for screening for ADPKD and ADPLD  \nS73 Table 7. Consequences of genetic testing by tNGS for people with typical or atypical ADPKD  \nS113 Table 8. Approaches to reduce AVP activity in ADPKD  \nS119 Table 9. Checklist of contraindications to initiating and/or maintaining tolvaptan use  \nS124 Table 10. Relative contraindications for increasing water intake S126 Table 11. Factors to be considered before advising increased water intake S135 Table 12. Classifications for PLD  \nS39 Table 13. Methods to assess sarcopenia and malnutrition  \nS139 Table 14. Treatment options in PLDS149 Table 15. Risk factors for ICAs or SAH  \nS42 Table 16. Advantages and limitations of screening for ICAs  \nS155 Table 17. Extrarenal manifestations  \nS44 Table 18. Nutrition guidance for people with ADPKD and CKD G1–G4  \nS163 Table 19. Recommendations on use of common lifestyle products in people with ADPKDS165 Table 20. Key concerns of people with ADPKD and their family members, relating to psychosocial issues S50 Table 21. Definitions of phenotypical entities in children with ADPKD  \nS192 Table 22. Clinica","cbCaihl5KVjEpxqk","https://ap.wps.com/l/cbCaihl5KVjEpxqk","pdf",9537380,240,"English","# Table list, figure list, and supplementary material\n## KDIGO Executive Committee\n## Reference keys\n## Current chronic kidney disease (CKD) nomenclature used by KDIGO\n## Conversion factors of conventional units to SI units\n## Equivalent albuminuria categories in CKD\n## Abbreviations and acronyms\n## Notice\n## Foreword\n## Dedication\n## Work Group membership\n## Abstract\n## Introduction from the Guideline Co-Chairs\n## Summary of recommendation statements and practice points\n## Chapter 1: Nomenclature, diagnosis, prognosis, and prevalence\n## Chapter 2: Kidney manifestations\n## Chapter 3: Chronic kidney disease (CKD) management and progression, kidney failure, and kidney replacement therapy (KRT)\n## Chapter 4: Therapies to delay the progression of kidney disease\n## Chapter 5: Polycystic liver disease\n## Chapter 6: Intracranial aneurysms and other extrarenal manifestations\n## Chapter 7: Lifestyle and psychosocial aspects\n## Chapter 8: Pregnancy and reproductive issues\n## Chapter 9: Pediatric issues\n## Chapter 10: Approaches to the management of people with ADPKD\n## Methods for guideline development\n## Appendix 1: Patient-reported outcome measures (PROMs) in ADPKD care\n## Appendix 2: Recommended checklist of issues to discuss at the beginning of the patient journey\n## Appendix 3: Patient organizations dealing with ADPKD or kidney disease in general, and other useful resources","[{\"question\":\"What conditions and topics does the KDIGO 2025 ADPKD guideline supplement cover?\",\"answer\":\"It covers evaluation and management of ADPKD across diagnosis, prognosis, and prevalence, kidney manifestations, CKD progression, kidney failure and kidney replacement therapy, and therapies intended to delay progression. It also addresses extrarenal manifestations including polycystic liver disease and intracranial aneurysms, plus lifestyle, psychosocial aspects, pregnancy and reproductive issues, and pediatric issues.\"},{\"question\":\"Which clinical chapters focus on delaying progression and related therapies?\",\"answer\":\"The supplement includes Chapter 4 on therapies to delay progression of kidney disease and also includes content on approaches to delay disease progression and reduce relevant biological activity, along with related contraindication and consideration tables.\"},{\"question\":\"Does the supplement include appendices for patient-centered outcomes and patient journey checklists?\",\"answer\":\"Yes. Appendix 1 lists patient-reported outcome measures (PROMs) in ADPKD care, Appendix 2 provides a recommended checklist of issues to discuss at the beginning of the patient journey, and Appendix 3 lists patient organizations and other useful resources.\"}]","KDIGO 2025 Clinical Practice Guideline - Autosomal Dominant Polycystic Kidney Disease (ADPKD) | PDF",605]